Literature DB >> 11325210

Incidence rate and management of prostate carcinoma.

G Sandblom1, E Varenhorst.   

Abstract

The age-standardised incidence of prostate cancer varies more than one hundredfold between the areas with the highest and lowest incidences in the world. In certain areas, in particular the Western countries, the incidence has increased rapidly over the last 20 years. There are several environmental and genetic factors which partly explain these variations, although the incidence probably depends most of all on the extent to which small latent tumours are detected. As the clinical significance of small tumours is uncertain, the value of early diagnosis and early aggressive treatment is controversial. Randomised trials addressing this question have been initiated and will hopefully provide more evidence-based data in a decade from now. Small localised tumours are managed by radical surgery or radiation therapy. In elderly men or men unfit for operation or radiation therapy surveillance is often preferred. For advanced or metastatic prostate cancers androgen deprivation has been the mainstay of treatment since the early 1940s. Recently, several new treatment strategies have evolved but have not yet been introduced into clinical routine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325210     DOI: 10.1016/s0753-3322(01)00038-5

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  1 in total

1.  DUP1 peptide modified micelle efficiently targeted delivery paclitaxel and enhance mitochondrial apoptosis on PSMA-negative prostate cancer cells.

Authors:  Haining Chen; Fengbo Wu; Jing Li; Xuehua Jiang; Lulu Cai; Xiang Li
Journal:  Springerplus       Date:  2016-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.